We read with interest several studies regarding correlated adherence to nucleos(t)ide analogues treatment with the occurrence of resistance or virological breakthrough(VB) [1–3]. These studies showed that poor adherence was associated with an increased risk of VB and resistance, with the incidence rate of resistance related to poor adherence ranging from 5.6 to 50%. These results were quite different. Therefore, we undertook a study to analyze possible trigger factors in the 926 CHB patients receiving NAs and VB.
